Ximelagatran

西米拉坦

Report date: 2023/03/15 13:41:36
NME

Base Information

Drug NameXimelagatran
Drug Alias NameXimelagatranum希美加群希美拉加群西美加群希美加曲 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProthrombin inhibitors
TargetsProthrombin
Therapy Area/IndicationsThromboembolismAtrial Fibrillation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryFrance
Original Approved Date2003/12/23
Country/TerritoryCzechiaBelgiumUnited States +[19] 
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsThromboembolismAtrial Fibrillation

Other Information

ATC CodeB01AE05
Related LinksWikipediaDrugBankKEGG